Rational Design and In Silico Evaluation of a Multiepitope Vaccine Targeting the uPAR for Cancer Immunotherapy

Area of Science:

• Immunology
• Computational Biology
• Vaccine Development

Background:

• Urokinase plasminogen activator receptor (uPAR) is a key factor in cancer progression.
• uPAR is a promising target for cancer immunotherapies.
• Developing effective uPAR-targeting vaccines is crucial.

Purpose of the Study:

• To design and evaluate a multiepitope vaccine targeting uPAR using immunoinformatics.
• To incorporate T cell epitopes and a toll-like receptor 4 (TLR4) agonist adjuvant.
• To assess the vaccine candidate's properties and immune response potential in silico.

Main Methods:

• Immunoinformatics tools were used to select uPAR T cell epitopes.
• Epitopes were assembled into a multiepitope vaccine construct with a TLR4 agonist adjuvant.
• In silico analyses included antigenicity, allergenicity, physicochemical properties, molecular docking, molecular dynamics, and immune simulations.

Main Results:

• The vaccine construct included five cytotoxic T lymphocyte (CTL) and five helper T lymphocyte (HTL) epitopes plus a TLR4 agonist.
• In silico predictions indicated the vaccine is nonallergenic, antigenic, soluble, and stable.
• Molecular docking showed high affinity to TLR4 (-334.37 kcal/mol), and simulations predicted a robust immune response with memory formation.

Conclusions:

• The designed multiepitope uPAR vaccine shows significant promise for cancer immunotherapy.
• Favorable in silico results support further experimental validation.
• This vaccine strategy could lead to effective cancer treatments targeting uPAR-expressing cells.